to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
Return to Top
Search Result Details
Back to Search Results
This page shows the details of why an item matched the keywords from your search.
One or more keywords matched the following items that are connected to
Extended efalizumab therapy sustains efficacy without increasing toxicity in patients with moderate to severe chronic plaque psoriasis.
A randomized, open-label trial of continuous versus interrupted etanercept therapy in the treatment of psoriasis.
Clinical efficacy of efalizumab in patients with chronic plaque psoriasis: results from three randomized placebo-controlled Phase III trials: part I.
Safety of efalizumab in adults with chronic moderate to severe plaque psoriasis: a phase IIIb, randomized, controlled trial.
Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis.
A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis.
Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials.
Efficacy and safety of ixekizumab over 4?years of open-label treatment in a phase 2 study in chronic plaque psoriasis.
Efficacy, safety, usability, and acceptability of risankizumab 150?mg formulation administered by prefilled syringe or by an autoinjector for moderate to severe plaque psoriasis.